Cancer Therapy : Preclinical NMS-E 973 , a Novel Synthetic Inhibitor of Hsp 90 with Activity against Multiple Models of Drug Resistance to Targeted Agents , Including Intracranial Metastases

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  2012influential reference
• Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.

  2012cited by this paper
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

  2012cited by this paper
• Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012cited by this paper
• Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

  2012cited by this paper
• The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

  2012cited by this paper
• HSP90 inhibitors for cancer therapy and overcoming drug resistance.

  2012cited by this paper
• TRAP-1, the mitochondrial Hsp90 ☆

  2012cited by this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

  2011cited by this paper
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

  2011cited by this paper
• The biology of brain metastases—translation to new therapies

  2011cited by this paper
• Mutant BRAF melanomas--dependence and resistance.

  2011cited by this paper
• Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

  2011cited by this paper
• Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

  2011cited by this paper
• Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?

  2011cited by this paper
• FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

  2011cited by this paper
• CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

  2011cited by this paper
• HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

  2011cited by this paper
• BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

  2011cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma

  2010cited by this paper
• BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

  2009cited by this paper
• CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

  2009cited by this paper
• DNA fingerprinting of the NCI-60 cell line panel

  2009cited by this paper
• SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

  2008cited by this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cited by this paper
• A Minimal Model of Tumor Growth Inhibition

  2008cited by this paper
• The ATPase Cycle of the Mitochondrial Hsp90 Analog Trap1*

  2008cited by this paper
• Heat shock protein 90: The cancer chaperone

  2007cited by this paper
• The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses

  2007cited by this paper
• ER chaperones in mammalian development and human diseases

  2007cited by this paper
• Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones.

  2007cited by this paper
• Analyzing a kinetic titration series using affinity biosensors.

  2006cited by this paper
• PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity

  2006cited by this paper
• Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

  2006cited by this paper
• Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

  2004cited by this paper
• Short tandem repeat profiling provides an international reference standard for human cell lines

  2001cited by this paper
• ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo

  1998cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase.

  1996cited by this paper
• Analysis of combined drug effects: a new look at a very old problem

  1983cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper

• No citing papers are available for this paper.